Literature DB >> 1749867

[Electrophysiological effect of verapamil on human atrium].

M Inoue1, D Inoue, I Omori, T Shirayama, Y Yamahara, J Asayama, H Katsume, M Nakagawa.   

Abstract

To investigate the effect of verapamil on atrial vulnerability, the following measurements were performed before and after the intravenous administration of verapamil (0.15 mg/kg) in 10 subjects with paroxysmal atrial fibrillation (Paf), and 10 subjects without Paf (non-Paf). During the sinus rhythm, 1) intra-/interatrial conduction time (Intra-/Inter- ACT); the initial deflection of high right atrium (HRA) to that of His bundel/coronary sinus were measured. After 8 consecutive HRA stimuli (A1), premature stimulus (A2) was introduced by shortening the coupling interval (A1A2) and we measured 2) conduction delay zone (CDZ); the zone of A1A2 with the prolongation of Inter-ACT, 3) % maximum atrial fragmentation (%MAF); % maximum value of the ratio of HRA activity width at A2 (Awt) against that at A1 (Awc), 4) fragmented atrial activity zone (FAZ); the zone of A1A2 with % value of Awt/Awc more than 150%,5) repetitive atrial response (RAR); more than 2 atrial activities which occur in response to A2. (6) right atrial effective refractory period (RAERP). Verapamil significantly shortened CDZ and %MFA, slightly lengthened RAERP, and had RAR disappear in Paf, while it did not effect any indices significantly in non-Paf. We concluded that verapamil could reduce atrial vulnerability in Paf due to blocking of atrial conduction delay mediated by slow response fibers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749867

Source DB:  PubMed          Journal:  Kokyu To Junkan        ISSN: 0452-3458


  1 in total

1.  Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

Authors:  C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.